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Feline lung monolayer cultures were treated with either a feline interferon (IFN) or one of two recombinant
human ft-IFNs and then challenged with feline herpesvirus 1 (FHV-1), feline calicivirus (F-9 strain), or
vesicular stomatitis virus. Treatment with these IFNs reduced the viral yield for each of these three viruses as
compared with that of control cultures. Vesicular stomatitis virus was more sensitive to each IFN than were
FHV-1 or feline calicivirus F-9.
Feline herpesvirus 1 (FHV-1) and feline caliciviruses
(FCV) are the major feline respiratory disease agents (4).
Each is estimated to cause 40 to 45% of feline respiratory
illness (10). Vaccines, including attenuated or killed FHV-1
and FCV strains, are available for controlling viral respira-
tory disease signs in feline infections with these viruses (4).
The usefulness of antiviral drugs against FHV-1 and FCV
infections in cats appears limited. In vitro ribavirin inhibits
replication and cytopathogenicity of FCV strain 255 but has
only slight effects on FHV-1 in a feline monolayer culture
system (1). Orally administered ribavirin did not affect the
clinical course of disease or viral excretions after aerosol
exposure to FCV strain 255 (12).
There are few studies on the susceptibility of the common
feline viruses to the antiviral action of interferon (IFN). This
study reports on the effects of recombinant human IFN and
a feline IFN when applied to feline monolayer cultures
subsequently challenged with feline viruses.
Feline lung (FL) cells obtained from the American Type
Culture Collection, Rockville, Md., were grown in culture
medium containing Eagle minimum essential medium (Earle
salts base) supplemented with 10% fetal bovine serum and
100 U of penicillin and 100 ,ug of streptomycin per ml and
incubated at 37°C in a humidified CO2 incubator. Mainte-
nance medium was the same except that 2% fetal bovine
serum was used.
FHV-1 C-27 strain (1), FCV F-9 strain (1), and vesicular
stomatitis virus (VSV) Indiana strain (7) were grown and
processed as described previously (5, 6) and titered by
plaque assay in FL cells (5) with titers expressed as PFU/0.1
ml.
Recombinant human IFN, Hu-oaA, and the hybrid Hu-
otA/D (Bgl) were obtained from the Roche Institute of
Molecular Biology, Nutley, N.J. (13). The feline IFN used in
this study (NDV-FL) was prepared by incubating 2 ml of
Newcastle Disease Virus suspension containing 2,560 HA
units (8) on a confluent FL monolayer in a 75-cm2 tissue
culture flask. The virus was removed after a 1-h adsorption
period; 20 ml of maintenance medium was then added, and
the monolayer culture was incubated at 37°C for 48 h. The
culture was frozen at -70°C and then thawed, after which
the suspension was centrifuged to remove cellular debris.
The supernatant fluid was dialyzed against pH 2.0 for 4 days,
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back dialyzed at pH 7.4 for 24 h, and ultracentrifuged at
105,000 x g for 1 h (7). The dialyzed and centrifuged samples
were assayed for IFN as described below.
IFN assays were performed by a plaque reduction method
in 24-well tissue culture plates containing confluent FL
monolayers with VSV as the challenge virus (6). IFN titers
(in units per milliliter) were expressed as the reciprocal of
the dilution that reduced the number of VSV plaques by
50%.
Preformed FL monolayers in 24-well tissue culture plates
were treated with IFN at 37°C for 18 to 24 h before viral
challenge for the yield reduction study for antiviral activity.
IFN dilutions were made in maintenance medium, and then
1.0 ml was added to each well (two wells per dilution). Virus
controls (not receiving IFN) were included in each experi-
ment. After the 18- to 24-h pretreatment with IFN, the IFN
was removed and each virus added in 0.1-ml volumes and
the virus adsorbed at 37°C for 1 h. After the 1-h adsorption,
wells received 1.0 ml of maintenance medium containing the
same IFN dilution as the IFN pretreatment. The cultures
were then incubated at 37°C. Due to low titers of available
IFN preparations, not all the same IFN concentrations were
used. The cultures were then collected at 24 h after viral
challenge and frozen at -70°C until assayed for infectivity.
Viral infectivity was measured by plaque assay in 24-well
plates using FL monolayers (5). Tenfold dilutions were made
(undiluted [100] was the lowest dilution tested), and 0.1 ml of
each dilution was added to the wells (two wells per dilution).
After 1 h of viral adsorption, 1.0 ml of overlay medium was
added to each well, and the plates were incubated at 37°C.
The plates were fixed and stained at 48 to 96 h after
inoculation. Viral yields were expressed as PFU per 0.1 ml.
IfPFU were not evident at 100 (undiluted), this was recorded
as negative.
FL cells incubated with IFN for 18 to 24 h before
challenge had yield reductions for FHV-1, FCV, and VSV in
the 24-h collections compared with cultures not receiving
IFN (virus controls). Comparisons between different IFN,
IFN concentrations, or amounts of viral challenge were not
always possible due to the lack of high IFN titers in stock
materials. VSV was the most sensitive to the antiviral effects
of each IFN tested (Table 1) compared to FHV-1 and
FCV-F9. With only 1,000 U of each IFN applied and the
largest viral challenge (1,000 PFU), there was greater than a
4 log10 PFU reduction due to IFN treatment against VSV.
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TABLE 1. Inhibition of VSV, FHIV-1, and FCV-F9 by
preparations of feline and human IFN
IFN Reduction in virus yield
concn Viral (log10)'
IFN treatment applied challenge
(IFN (PFU) VSV FHV-1 FCV-F9
U/ml)
NDV-FL 1,000 1,000 5.0 2.3 3.3
HuIFN-ctA 1,000 100 5.6 1.4 2.1
1,000 1,000 4.7 1.4 1.6
HuIFN-coA/D 10,000 100 6.1 3.1 4.3
10,000 1,000 5.3 3.1 3.1
1,000 100 5.6 3.0 3.9
1,000 1,000 4.8 2.7 3.2
Yield is expressed as PFU/0.1 ml of culture fluids, and the titer represents
the mean of three individual experiments. The titers in cultures not receiving
IFN were: (i) VSV, 1,000 PFU challenge (106.1) and 100 PFU challenge (106 1);
(ii) FHV-1, 1,000 PFU challenge (104 8) and 100 PFU challenge (103 7); and (iii)
FCV-F9, 1,000 PFU challenge (106.4) and 100 PFU challenge (106 3).
When the IFN concentration was the highest (10,000 U) and
the viral challenge the lowest (100 PFU), the yield reductions
were the greatest. This was true for each of the viruses
tested. FHV-1 was also sensitive to each IFN (Table 1).
There was at least a 1.4 log1o PFU reduction when each IFN
was used in cultures challenged with FHV-1. The greatest
reduction for FHV-1 (>3 log1o PFU) occurred with 10,000 U
of HuIFN-oxA/D with a viral challenge of 100 PFU. FCV-F9
was also sensitive to each IFN (Table 1). There was at least
a 1.6 log1o PFU reduction for FCV-F9. Similar to that with
VSV and FHV-1, the greatest reduction (>4 log1o PFU)
occurred with 10,000 U of HuIFN-cxA/D treatment and a
viral challenge of 100 PFU. Of the two recombinant Hu-cx
IFNs, the hybrid HuIFN-(xA/D had greater antiviral effects
than HuIFN-cxA. At the 1,000 IFN concentration and at both
viral challenge concentrations (100 or 1,000 PFU), the viral
yields for both FHV-1 and FCV-F9 were reduced to a
greater extent by the HuIFN-oxA/D treatment compared to
the HuIFN-otA treatment.
There are relatively few reports on the activity of IFN
against naturally occurring feline viruses. A feline IFN
produced by Newcastle disease virus-exposed feline
monolayer cultures inhibited feline leukemia virus (FeLV)
replication in IFN-treated feline monolayer cultures (14).
FeLV was inhibited by the treatment of feline cell lines with
Sendai virus-induced crude HuIFN-oL (9). Both natural
HuIFN-ot and several recombinant HuIFN-ot, including hy-
brids, reduced FeLV production by F1F3 cells, a feline
fibroblast line chronically infected with FeLV (15). In a
recent report, a feline IFN (y-like) produced by feline
lymphocytes treated with Staphylococcus enterotoxin A
inhibited FCV-F9 but not FHV-1 (3). However, the latter
study utilized a plaque reduction assay instead of the yield
reduction assay used in the present study. There were also
differences in the sources of IFN used in these studies. Thus,
different assay systems and IFN sources may explain the
variation between our results and those of the previous study
(3).
The results of the present study indicate that recombinant
human IFN and a feline IFN conferred protection against
FHV-1 and FCV, both naturally occurring viral pathogens in
the cat. Thus, there may be potential for these IFN as
antiviral agents used in prophylaxis or therapy against these
infections. The use of such IFN takes on even greater
importance since FeLV-infected cats often have FHV-1 or
FCV infections (2). FeLV has several immunosuppressive
properties including the inhibition of IFN production by
feline lymphocytes treated with a mitogen (3). Thus, IFN
treatfnent might protect cats against FeLV infection and
FHV-1 and FCV infections in FeLV-immunosuppressed
cats.
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